Science and Technology Resources

OSTR支持哺乳动物细胞中的许多蛋白质表征分析 为CCR研究人员通过蛋白质表征实验室在弗雷德里克 国家实验室（FNL）。OSTR继续评估所有商业平台， 蛋白质和基因表达谱分析以及其它高通量技术。使 CCR研究人员很容易获得的最新进展，OSTR已经建立了一些 与提供基因组学和代谢组学分析技术的公司达成安排， 服务这些协议大大降低了成本，并为CCR提供了一种高效简便的方法 研究人员使用这些技术。已制定了一项补贴计划， 资助CCR研究人员获得先进的基因组学、蛋白质组学、代谢组学和 生物信息技术这种资助机制有助于扩大有限的研究 向CCR实验室提供200万美元，并允许我们的研究人员进行实验 否则这可能是成本过高的。许多受资助的项目导致了重要的 在顶级期刊上发表文章。最近，OSTR参与了CCR的工作 获得下一代测序技术，包括建立一个新的 单细胞分析设施现在位于41号楼，可供任何CCR使用 调查员为了满足CCR快速增长的管理和分析大量 基因组和蛋白质组数据，OSTR已经与生物信息学建立了几个合作伙伴关系 企业在为NCI节省大量成本的情况下，OSTR谈判了各种许可协议 代表所有NCI研究人员普遍获得先进的生物信息学工具， 微阵列实验的统计分析、蛋白质组学分析研究和基因组学分析。 包括下一代测序数据的分析。此外，OSTR还提出了一些 用于研究途径和生物关联网络的软件应用 提供给所有NCI。OSTR继续评估CCR在以下领域的要求： 生物信息学和生物统计学。我们继续与Leidos生物医学研究（LBR）合作， 创建CCR专用生物信息学计划，为CCR研究者提供支持。支持 用于分析高通量基因组和蛋白质组学数据， 这个新项目位于贝塞斯达校园。最近，OSTR采取了 关于蛋白质技术合作的纳米蛋白质组学部分的管理 Resource.该核心对所有CCR研究者开放，致力于开发和 实施尖端的基于蛋白质的技术，以促进发现，翻译 和临床研究在CCR/NCI/NIH。该核心提供专业知识，并提供最先进的 满足CCR/NCI/NIH研究人员需求的技术：快速和精确 蛋白质分析;全面和定量的细胞信号事件解剖;纳米尺度 定量蛋白质组学评估;生物标志物开发和治疗靶点 鉴定;以及，临床适用的测定开发和应用。最近， CPTR为CCR社区提供空间蛋白质组学和转录组学。该芯 单独报告。

The OSTR is supporting a number of protein characterization analyses in mammalian cells for CCR investigators through the Laboratory of Protein Characterization at the Frederick National Lab (FNL). The OSTR continues to evaluate all commercially available platforms for protein and gene expression profiling and other high throughput technologies. To make the latest advances easily accessible to CCR researchers, the OSTR has established a number of arrangements with companies providing genomic and metabolomic profiling technologies and services. These agreements have led to far lower cost and an efficient and easy way for CCR investigators to access these technologies. A subsidy program has been established providing subsidies to support CCR investigator access to advanced genomic, proteomic, metabolomic, and bioinformatic technologies. This funding mechanism has helped to extend the limited research dollars available to CCR laboratories and has permitted our researchers to conduct experiments that might otherwise be cost prohibitive. Many of the funded projects have led to important publications in top-tier journals. Most recently, the OSTR has been involved in CCR's efforts to access the next generation sequencing technologies, including the setting up of a new single cell analysis facility now located building 41, which is available to any CCR investigator. In response to CCR's rapidly growing need to manage and analyze large sets of genomic and proteomic data, the OSTR has developed several partnerships with bioinformatics companies. At significant cost savings to NCI, OSTR negotiated a variety of license agreements on behalf of all NCI researchers for universal access to sophisticated tools for bioinformatic and statistical analysis of microarray experiments, proteomic profiling studies, and genomic analysis including next-generation sequencing data. In addition, the OSTR has made a number of software applications for the investigation of pathways and biological association networks available to all of NCI. The OSTR continues to assess CCR's requirements in the area of bioinformatics and biostatistics. We continue to work with Leidos Biomedical Research (LBR) to create a CCR dedicated Bioinformatics Program to provide support to CCR investigators. Support for analysis of high throughput genomic and proteomic data is being made available through this new program, which is located on the Bethesda campus. Most recently, the OSTR has taken on the management of the NanoScale Proteomics section of the Collaborative Protein Technology Resource. This Core is an open to all CCR investigators and dedicated to developing and implementing cutting-edge protein-based technologies to facilitate discovery, translational and clinical research in CCR/NCI/NIH. This Core offers expertise and provides state-of-the-art technologies to accommodate the demands of CCR/NCI/NIH investigators for: Rapid and precise protein analysis; Comprehensive and quantitative cell signaling event dissection; Nanoscale quantitative proteomics assessment; Biomarker development and therapeutic target identification; and, Clinical applicable assay development and applications. Most recently, the CPTR is offering spatial proteomics and transcriptomics to the CCR community. This Core is reported separately.